Actively Recruiting
Open-label Dose-Escalation Study of Oral D3S-003 for Advanced Solid Tumors with KRAS p.G12D Mutation
Led by D3 Bio (Wuxi) Co., Ltd · Updated on 2026-09-08
42
Participants Needed
9
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating D3S-003, an oral drug, in a first-in-human Phase 1 clinical trial for participants with advanced solid tumors that have a specific KRAS p.G12D mutation. This trial aims to assess the safety, tolerability, how the drug is processed by the body, its biological effects, and early signs of how well it might work. Participants must have cancers that have not responded to standard treatments or have no effective standard options, and tumors that can be measured by imaging. The study includes two parts of dose escalation to find the best dosing schedule once daily and twice daily dosing of D3S-003. Participants will receive the drug orally with doses gradually increased to evaluate safety and identify the maximum tolerated dose and recommended Phase 2 dose. The treatment period can last up to approximately seven months or until disease progression or unacceptable side effects occur. During the study, participants will have regular monitoring for side effects and safety from the screening visit until 30 days after the last dose. Researchers will measure drug levels in the blood and evaluate tumor response using standardized criteria. The primary outcomes include the number of participants experiencing dose-limiting toxicities and adverse events. The trial will last until January 2028, with frequent assessments during treatment cycles of 21 days each.
CONDITIONS
Brief Title
A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.
Research Team
M
Medical Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here